Alginic acid radical biomaterial with developing function and preparation method thereof

A technology of biomaterials and alginic acid, which is applied in the field of developable alginic acid-based biomaterials and its preparation, can solve the problems of insufficient mechanical support, large heart trauma of patients, and high difficulty of surgical operation, so as to facilitate real-time monitoring and control, The effect of wide application and high risk reduction

Active Publication Date: 2018-09-28
NINGBO DIOCHANGE MEDICAL TECH CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In view of this, the object of the present invention is to provide an imageable alginic acid-based biomaterial that can be easily implanted into the ventricular wall for adjuvant treatment of heart failure by means of minimally invasive vascular interventional surgery injection and implantation, and its preparation method. In order to solve the existing technolo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alginic acid radical biomaterial with developing function and preparation method thereof
  • Alginic acid radical biomaterial with developing function and preparation method thereof
  • Alginic acid radical biomaterial with developing function and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0052] Put the developable alginic acid-based biomaterial that has been fully mixed according to the preparation method provided by the present invention in a cylindrical cavity mold, and after the developable alginic acid-based biomaterial sample is fully gelled, it is made into a diameter of 20 mm and a height of 20 mm. For a 20mm cylindrical sample, use a universal testing machine to test the support strength of the sample, set the pressurization speed to 2mm / min, and the clamping distance to 20mm, and obtain the support strength of the sample directly from the data output by the universal testing machine.

[0053] Multiple target injection experiment of minimally invasive vascular intervention surgery injection implantation:

[0054] The developable alginic acid-based biological material that has been fully mixed according to the preparation method provided by the present invention is subjected to animal experiments. The animal experiment object is a pig, and the femoral ...

Embodiment 1

[0069] (1) Premixing stage

[0070] (1) Preparation of a premix containing component B, component C and component D (i.e.: crosslinking agent+developer system): weigh the calculated amount of component B (calcium alginate, solid particle size of 75 μm), the three powders of component C (iohexol) and component D (mannitol) are dissolved in water for injection together, fully dissolved, so that component B, component C and component D are in this premix The contents are 1.5% (g / ml), 75.5% (g / ml) and 302mmol / L respectively, and this premixture is formed into a water-soluble solution, and the pH value of this solution is 3.9.

[0071] (2) Preparation of a premix containing component A and component D (i.e. sodium alginate system): weigh the calculated amount of component A (sodium alginate, molecular weight is 180kDa) and component D (mannitol) These two kinds of powders are dissolved in water for injection together, fully dissolved, make the content of component A and component ...

Embodiment 2

[0076] (1) Premixing stage

[0077] (1) Preparation of a premix containing component B, component C, component D and component E (ie: crosslinking agent+developer system): weigh the calculated amount of component B (calcium alginate, solid Particle size is 75 μ m), these three kinds of powders of component C (iohexol) and component D (mannitol) are dissolved in water for injection together, fully dissolved, make component B, component C and component D in The content in this premixture is respectively 1.5% (g / ml), 75.5% (g / ml) and 302mmol / L, selects sodium hydroxide as component E regulator at last, makes the pH value of premixture promote from 3.9 to 7.0, the final premix is ​​a water-soluble solution.

[0078] (2) (2) with embodiment 1 description.

[0079] (2) Reaction stage

[0080] (3) (3) with embodiment 1 description.

[0081] (4) Stable biomaterials can be formed in 6.17min of equilibrium, and the content of component A, component B, component C and component D in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to an alginic acid radical biomaterial with a developing function and a preparation method thereof. The alginic acid radical biomaterial is prepared from a group A, a group B, agroup C and the balance injection water, wherein the group A includes water-soluble alginate, and the content of the alginate in the alginic acid radical biomaterial is 0.1-10% (g/ml); the group B includes a cross-linking agent containing divalent or polyvalent metal cations, and the content of the cross-linking agent in the alginic acid radical biomaterial is 0.1-10% (g/ml); the group C includesa developing agent, the developing agent is a liquid agent or powdery agent with the developing function for medical use, and the content of the developing agent in the alginic acid radical biomaterial is 0.001-260% (g/ml). The biomaterial provides convenience for adopting a minimally invasive blood vessel interventional operation for injection and implantation, the mechanical supporting performance is uniform and stable, clinically required key performance indexes, such as a gelatinization process and mechanical supporting performance, can be adjusted and controlled by means of premixing andother various measures, and therefore sufficient mechanical supporting efficacy is achieved. The histocompatibility is high, the operation difficulty of the operation is low, the application range iswide, the risk is small, and the safety effectiveness is high.

Description

technical field [0001] The invention relates to the field of alginic acid-based biomaterials, in particular to a developable alginic acid-based biomaterial for auxiliary treatment of heart failure and a preparation method thereof. Background technique [0002] Heart failure, also known as heart failure, refers to the failure of the venous blood to fully discharge the heart due to the impairment of the systolic and diastolic functions of the heart, resulting in blood stasis in the venous system and insufficient blood perfusion in the arterial system, thereby causing cardiac circulation disorders. One of the main pathogenesis of heart failure is pathological remodeling of the ventricle, which is mainly manifested as changes in the shape and structure of the left ventricle, such as ventricular dilatation, hypertrophy, spherical enlargement, etc., and these changes will further aggravate the deterioration of the patient's clinical symptoms . The current treatment of heart failu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/04A61L31/14A61L31/18
CPCA61L31/042A61L31/14A61L31/18A61L2400/06C08L5/04
Inventor 李彪陈琦陈超
Owner NINGBO DIOCHANGE MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap